Search
-
Gsk Rdday Part2 Vaccines Dr Moncef Slaoui Final
Media
https://www.gsk.com/media/8209/gsk-rdday-part2-vaccines-dr-moncef-slaoui_-final.pdf
First published: 06 June 2022
-
RSV Season 2 PR
Media
https://www.gsk.com/media/10267/rsv-season-2-pr.pdf
First published: 21 June 2023
-
Sanofi and GSK confirm agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine
Media
This confirmation follows the announcement on 31 July of advanced discussions between the companies and the EC.
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-confirm-agreement-with-european-union-to-supply-up-to-300-million-doses-of-adjuvanted-covid-19-vaccine/
First published: 18 September 2020
-
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
Media
Over 400 participants being enrolled in Phase 1/2 study.
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate/
First published: 03 September 2020
-
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
Media
New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults.
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-new-phase-2-study-of-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-candidate/
First published: 22 February 2021
-
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Media
Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant.
https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/
First published: 12 November 2020
-
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
Media
Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years
https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-announce-a-delay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-programme-to-improve-immune-response-in-the-elderly/
First published: 11 December 2020
-
GSK grants exclusive technology license for clinical-stage Ebola vaccines to Sabin Vaccine Institute
Media
Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines
https://www.gsk.com/en-gb/media/press-releases/gsk-grants-exclusive-technology-license-for-clinical-stage-ebola-vaccines-to-sabin-vaccine-institute/
First published: 06 August 2019
-
Press Release Arexvy File Acceptance US 50 59
Media
https://www.gsk.com/media/10948/press-release-arexvy-file-acceptance-us-50-59.pdf
First published: 06 February 2024
-
Randd Day Vaccines Session
Media
https://www.gsk.com/media/8207/randd-day-vaccines-session.pdf
First published: 06 June 2022